This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Hematology/ Hematologic Malignancies  • Coagulation Disorders  • Ophthalmological Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Ophthalmol. 2004;122:1543-1544.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Acetazolamide (Diamox; Duramed Pharmaceuticals Inc, Cincinnati, Ohio) is a carbonic anhydrase inhibitor commonly used in ophthalmology to reduce intraocular pressure and to treat some forms of macular edema. Acetazolamide-associated thrombocytopenia was previously described as part of aplastic anemia or other organ involvement; however, evidence that the drug may also cause accelerated platelet destruction has never been provided.^1-2 Herein we report an acetazolamide-induced pure thrombocytopenia with the highest level of evidence for a causal relationship of the drug to thrombocytopenia.

Report of a Case

A 67-year-old man who had been receiving metformin for 20 years because of type 2 diabetes mellitus was admitted to our department for cataract surgery. The day after the surgery, intraocular pressure was elevated and 2 daily 250-mg tablets of acetazolamide were prescribed. As the intraocular pressure normalized on day 3, acetazolamide was stopped. A routine blood cell count with examination of the blood smear disclosed an unexpected and isolated thrombocytopenia . . . [Full Text of this Article]

Comment
Laurent Kodjikian, MD, PhD; Brigitte Durand, PhD; Carole Burillon, MD; Frédéric Rouberol, MD; Jean-Daniel Grange, MD; Philippe Renaudier, MD

Correspondence: Dr Renaudier, Department of Hematology, Croix-Rousse Hospital, 103, grande rue de la Croix-Rousse, Lyon 69004, France (philippe.renaudier@chu-lyon.fr).